[Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer].

Song, Xu; Jian-Ping, Gao; Wen-Quan, Zhou

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2009

Data sources: Europe PubMed Central

[Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer].

descriptionPublicationkeyboard_double_arrow_right Article 15 May 2009Journal:Zhonghua nan ke xue = National journal of andrology, volume 14 (issn: 1009-3591,

Copyright policy )

Authors: Song, Xu; Jian-Ping, Gao; Wen-Quan, Zhou;

pmid: 19102508

[Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer].

- Summary
- Subjects
- Metrics

Abstract

Cyclooxygenase-2 (Cox-2) is over-expressed in prostate cancer (PCa) and involved in its development and progression by facilitating inflammatory response, reducing cell apoptosis, increasing angiogenesis and damaging DNA oxidation. Selective Cox-2 inhibitors suppress PCa growth through various channels and therefore have a promising application value in the management of prostate cancer.

Keywords

Male, Cyclooxygenase 2 Inhibitors, Cyclooxygenase 2, Humans, Prostatic Neoplasms, Apoptosis

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average